Clinical trial
Phase I Study to Evaluate Cellular Immunotherapy Using Memory-Enriched T Cells Lentivirally Transduced to Express a CD19-Specific, Hinge-Optimized, CD28-Costimulatory Chimeric Receptor and a Truncated EGFR Following Lymphodepleting Chemotherapy in Adult Patients With CD19+ B-Cell Lymphoproliferative Neoplasms
NCT02153580 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase I Study to Evaluate Cellular Immunotherapy Using Memory-Enriched T Cells Lentivirally Transduced to Express a CD19-Specific, Hinge-Optimized, CD28-Costimulatory Chimeric Receptor and a Truncated EGFR Following Lymphodepleting Chemotherapy in Adult Patients With CD19+ B-Cell Lymphoproliferative Neoplasms
- Lead sponsor
- City of Hope Medical Center
- Phase
- Phase 1
- Overall status
- Active, not recruiting
- Start date
- September 24, 2014
- Completion date
- August 11, 2027
- Enrollment
- 37 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
b-cell lymphoma, unclassifiable, with features intermediate between diffuse large b-cell lymphoma and classic hodgkin lymphoma, b-cell prolymphocytic leukemia, high grade b-cell lymphoma, not otherwise specified, post-transplant lymphoproliferative disorder, recurrent adult burkitt lymphoma, recurrent chronic lymphocytic leukemia, recurrent diffuse large b-cell lymphoma, recurrent follicular lymphoma, recurrent hairy cell leukemia, recurrent lymphoplasmacytic lymphoma, recurrent mantle cell lymphoma, recurrent marginal zone lymphoma, recurrent small lymphocytic lymphoma